Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.
about
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AThe evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.Linking medicine and economics: health economics and quality of life in haemophilia care.Clinimetric instruments to assess functional health status in patients with haemophilia: a literature review.A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.Gene therapy ethics and haemophilia: an inevitable therapeutic future?Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.A global view on prophylaxis: possibilities and consequences.When to start and when to stop primary prophylaxis in patients with severe haemophilia.North American prophylaxis studies for persons with severe haemophilia: background, rationale and design.Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.Economics of prophylactic treatment.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Central venous access devices in haemophilia.Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?Treatment of hemophilia: a review of current advances and ongoing issuesShort-term exposure of cartilage to blood results in chondrocyte apoptosis.Dose and response in haemophilia--optimization of factor replacement therapy.Optimizing factor prophylaxis for the haemophilia population: where do we stand?Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.New treatments in hemophilia: insights for the clinician.Scoring haemophilic arthropathy on X-rays: improving inter- and intra-observer reliability and agreement using a consensus atlasOptimizing outcomes for patients with severe haemophilia A.Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience.Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.Primary prophylaxis in children with haemophilia.Novel drugs to treat hemophilia.Haemophilia prophylaxis: how can we justify the costs?Importance of pharmacokinetics in the management of hemophilia.Hemophilia and prophylaxis.The burden of bleeding in haemophilia: is one bleed too many?Changing paradigm of prophylaxis with longer acting factor concentrates.Methods for individualising factor VIII dosing in prophylaxis.Assessments of outcome in haemophilia - what is the added value of QoL tools?Real-world resource use and costs of haemophilia A-related bleeding.Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia.Low dose prophylaxis in Tunisian children with haemophilia.Personalized prophylaxis.
P2860
Q24234413-456EA7AC-9EE1-4E85-A232-28BBB13F5735Q28075081-62D78296-8934-4B4A-BBF6-55D92E4E2E02Q30249256-EEE957B8-15CB-4AC0-A2B6-A242776AF227Q30832356-7B7B09A6-ED71-44E3-A4D7-F1426A5E09FBQ34636921-3D101079-9FB1-41CA-A7B7-390FFDF8D1E6Q34637110-23FD9406-ED3D-448B-8ED1-D9F6A79403B5Q34890523-5736AFFF-784D-4461-9FD3-BD3FBD8DE6CAQ35076713-67954389-0E1B-4890-91E3-DC83A7B9C9C8Q35106858-061BAF2A-073E-4F27-A086-3B44C7AEBD16Q35112430-B070E991-B805-429F-92B8-B543BCCFFFACQ35112433-D5450660-63B3-4D7D-A128-80DB6016226DQ35112437-64C817D2-E97B-4DC4-AE23-D7F532E132F4Q35112459-992D5030-9766-4032-9117-D81ADE9E3FD6Q35112463-A9F3AEBA-0E41-4896-8D59-0B058861462BQ35565320-82420DB4-4F4D-46F1-83C5-8049DDCBC186Q35666735-D0B45847-0289-4176-A269-0ED8727A280AQ35666740-AF72A533-F8CA-4D0C-B364-EE6F48051401Q35683781-2FFEE854-B1FF-46A1-8267-44B633807075Q35791362-BCEB0335-A1C4-4917-A6E7-BADD1684116FQ35895845-8EFBFC3E-42C8-4F12-A7B1-4A3E30F0865FQ35915686-1A8CB529-E984-4E14-B893-1DE410C36DE6Q36189452-7C891D23-4247-4544-9697-45B4E7289D78Q36612681-956DA986-55CB-44EF-9017-34FC4BA6B971Q36908311-F230989D-8D4A-441E-9BA1-2A5D71039E71Q36932769-EF3939F5-97A5-4E55-B133-B2713DFAE5FDQ37052161-A8239675-9ADE-4440-9BC0-C2EBE2998A34Q37057618-983789BB-F41E-4C6E-9FC8-72277890F594Q37119644-D517C2A7-1C3E-47CD-A9CB-761BA376AF53Q37775029-FA436AB5-F004-4EF9-BE87-02D270C393A1Q38002994-ED291FF9-E324-432D-92AD-895F20F100A6Q38056463-B8F6A066-CA2D-4428-8C8C-3D6C0B1D13FDQ38056467-A3FA6B38-F3A7-4F7B-B9A8-07BC66519790Q38182702-3849F82D-456A-4BB9-9F05-E6BBE58EF99FQ38206858-2A3DEB2C-1DC4-4D55-B1E2-02AFDE31E118Q38222572-01A078B6-2362-4CFC-A1A3-E0614B5D0CB0Q38511447-D2EB062B-6890-49F0-B292-6B72FAE2B024Q38675749-CF644337-0D32-4607-BBE8-73A060AD0078Q38843540-1BDD27A3-BE9D-4CD3-9976-228A95CDE540Q39030128-86A191B9-00A0-46E2-A3D1-F9559009CF6EQ39596251-4D38987E-75F8-4AA7-98CF-63093A17E3E8
P2860
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Long-term outcome of individua ...... ldren with severe haemophilia.
@en
Long-term outcome of individua ...... ldren with severe haemophilia.
@nl
type
label
Long-term outcome of individua ...... ldren with severe haemophilia.
@en
Long-term outcome of individua ...... ldren with severe haemophilia.
@nl
prefLabel
Long-term outcome of individua ...... ldren with severe haemophilia.
@en
Long-term outcome of individua ...... ldren with severe haemophilia.
@nl
P2093
P2860
P1476
Long-term outcome of individua ...... ldren with severe haemophilia.
@en
P2093
Mauser-Bunschoten EP
Nieuwenhuis HK
Roosendaal G
van den Berg HM
van der Bom JG
P2860
P304
P356
10.1046/J.1365-2141.2001.02580.X
P407
P577
2001-03-01T00:00:00Z